
Novo Nordisk Q1 operating profit down 10% in local currencies
pharmafile | April 29, 2016 | News story | Medical Communications, Sales and Marketing |Â Â Financial, Novo Nordisk, Q1, earnings, outlook, resultsÂ
Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year sales forecast.
Operating profit at 12.31 billion Danish crowns ($1.88 billion) was down against 13.86 billion Danish crowns a year ago.
The company reported earnings per share of 3.71 Danish crowns ($0.57), down 2.1% versus a year ago. Sales grew 8% to 27.2 billion Danish crowns.
Chief Executive Lars Rebien Sørensen, said: “We are pleased with the results during the first quarter of 2016 where Victoza and Tresiba both delivered significant growth.”
For 2016, Novo Nordisk still expects sales growth of 5% to 9% in local currencies. The company sees adjusted operating profit growth of 5% to 9% in local currencies.
All regions contributed to sales growth; however, US was the main contributor with 64% share of growth measured in local currencies, followed by international operations and the new sales region Pacific contributing 23% and 6%, respectively, the company said in a statement.
Sales growth in the US was boosted by about 3% from nonrecurring adjustments to rebates in the Medicaid patient segment.
Anjali Shukla
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …






